Amneal Eyes Avastin And Praises $120m Biosimilar Development Savings
‘We Are Here To Stay’ US Firm Says Of Biosimilar Ambitions
Executive Summary
Amneal is close to a filed pipeline of three biosimilar products in the US, while furthering ambitions in the complex generics and 505(b)(2) space, management told the virtual J.P. Morgan Healthcare Conference.
You may also be interested in...
Amneal Completes Kashiv Takeover
Amneal says it has taken the latest step towards “Amneal 2.0” after completing its deal to acquire Kashiv Specialty Pharmaceuticals.
Amneal’s Generics Business Reinvigorated By New Launches
As Amneal’s generics segment sees significant growth, the company has revealed plans to launch new products and expand in new markets. “We are extremely proud of the progress our company has made since we re-joined as leaders of Amneal,” said Chirag and Chintu Patel, co-CEOs of Amneal.
Teva Takes On Amneal With Second US NuvaRing Rival
Teva has launched its generic version of NuvaRing in the US, adding a second rival generic to the market that already includes Amneal, as well as an authorized generic version from Prasco.